News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
706,961 Results
Type
Article (40139)
Company Profile (249)
Press Release (666569)
Multimedia
Podcasts (63)
Webinars (14)
Section
Business (204352)
Career Advice (2011)
Deals (35461)
Drug Delivery (97)
Drug Development (81164)
Employer Resources (172)
FDA (16269)
Job Trends (14896)
News (345630)
Policy (32626)
Tag
Academia (2556)
Accelerated approval (13)
Adcomms (22)
Allergies (99)
Alliances (49572)
ALS (112)
Alzheimer's disease (1487)
Antibody-drug conjugate (ADC) (154)
Approvals (16282)
Artificial intelligence (326)
Autoimmune disease (29)
Automation (22)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (125)
Biotechnology (174)
Bladder cancer (102)
Brain cancer (37)
Breast cancer (385)
Cancer (3023)
Cardiovascular disease (226)
Career advice (1682)
Career pathing (30)
CAR-T (192)
CDC (32)
Cell therapy (520)
Cervical cancer (23)
Clinical research (67089)
Collaboration (1069)
Company closure (3)
Compensation (756)
Complete response letters (28)
COVID-19 (2636)
CRISPR (60)
C-suite (379)
Cystic fibrosis (115)
Data (3240)
Decentralized trials (2)
Denatured (21)
Depression (66)
Diabetes (355)
Diagnostics (6451)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (147)
Drug pricing (128)
Drug shortages (28)
Duchenne muscular dystrophy (154)
Earnings (88199)
Editorial (42)
Employer branding (21)
Employer resources (148)
Events (113969)
Executive appointments (866)
FDA (18193)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (963)
Gene editing (136)
Generative AI (23)
Gene therapy (402)
GLP-1 (803)
Government (4533)
Grass and pollen (5)
Guidances (310)
Healthcare (18840)
HIV (41)
Huntington's disease (30)
IgA nephropathy (43)
Immunology and inflammation (160)
Immuno-oncology (10)
Indications (42)
Infectious disease (2818)
Inflammatory bowel disease (152)
Inflation Reduction Act (10)
Influenza (71)
Intellectual property (129)
Interviews (312)
IPO (16595)
IRA (47)
Job creations (3637)
Job search strategy (1424)
Kidney cancer (13)
Labor market (57)
Layoffs (507)
Leadership (19)
Legal (7931)
Liver cancer (81)
Longevity (11)
Lung cancer (419)
Lymphoma (222)
Machine learning (15)
Management (58)
Manufacturing (433)
MASH (96)
Medical device (13496)
Medtech (13506)
Mergers & acquisitions (19627)
Metabolic disorders (874)
Multiple sclerosis (100)
NASH (16)
Neurodegenerative disease (136)
Neuropsychiatric disorders (36)
Neuroscience (2214)
NextGen: Class of 2025 (6517)
Non-profit (4489)
Now hiring (50)
Obesity (436)
Opinion (221)
Ovarian cancer (104)
Pain (116)
Pancreatic cancer (131)
Parkinson's disease (192)
Partnered (23)
Patents (327)
Patient recruitment (189)
Peanut (50)
People (57809)
Pharmaceutical (63)
Pharmacy benefit managers (21)
Phase I (20891)
Phase II (29545)
Phase III (22000)
Pipeline (2001)
Policy (213)
Postmarket research (2564)
Preclinical (8903)
Press Release (64)
Prostate cancer (147)
Psychedelics (37)
Radiopharmaceuticals (253)
Rare diseases (479)
Real estate (5917)
Recruiting (66)
Regulatory (22825)
Reports (50)
Research institute (2327)
Resumes & cover letters (350)
Rett syndrome (9)
RNA editing (9)
RSV (53)
Schizophrenia (97)
Series A (158)
Series B (115)
Service/supplier (11)
Sickle cell disease (62)
Special edition (18)
Spinal muscular atrophy (148)
Sponsored (33)
Startups (3592)
State (2)
Stomach cancer (14)
Supply chain (78)
Tariffs (65)
The Weekly (40)
Vaccines (809)
Venture capital (58)
Weight loss (266)
Women's health (48)
Worklife (16)
Date
Today (144)
Last 7 days (767)
Last 30 days (2240)
Last 365 days (30990)
2025 (18851)
2024 (35219)
2023 (40076)
2022 (51175)
2021 (55711)
2020 (54083)
2019 (46538)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37554)
2014 (31319)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (724)
Alabama (64)
Alaska (7)
Arizona (246)
Arkansas (13)
Asia (38300)
Australia (6247)
California (7906)
Canada (2467)
China (701)
Colorado (332)
Connecticut (338)
Delaware (207)
Europe (82376)
Florida (1198)
Georgia (264)
Hawaii (2)
Idaho (60)
Illinois (657)
India (29)
Indiana (379)
Iowa (17)
Japan (240)
Kansas (111)
Kentucky (30)
Louisiana (16)
Maine (64)
Maryland (1078)
Massachusetts (5862)
Michigan (253)
Minnesota (481)
Mississippi (4)
Missouri (97)
Montana (28)
Nebraska (25)
Nevada (87)
New Hampshire (67)
New Jersey (2183)
New Mexico (28)
New York (2178)
North Carolina (1121)
North Dakota (8)
Northern California (3526)
Ohio (247)
Oklahoma (16)
Oregon (34)
Pennsylvania (1709)
Puerto Rico (17)
Rhode Island (38)
South America (1098)
South Carolina (36)
South Dakota (1)
Southern California (2997)
Tennessee (131)
Texas (1189)
United States (29102)
Utah (230)
Virginia (195)
Washington D.C. (72)
Washington State (661)
West Virginia (4)
Wisconsin (69)
706,961 Results for "regenxbio inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Duchenne muscular dystrophy
Regenxbio Fails To Best Sarepta’s Elevidys With New Data for DMD Gene Therapy
Interim results from a small group of children in a Phase I/II trial are essentially in line with that of Elevidys, according to BMO Capital Markets analysts.
June 5, 2025
·
2 min read
·
Dan Samorodnitsky
Gene therapy
Regenxbio Jumps on Potential $800M Rare Disease Deal With Nippon Shinyaku
In exchange for its investigational gene therapies, Regenxbio will receive $110 million upfront and up to $700 million in milestones. After hitting an all-time low of $6.95 at close of business yesterday, the stock surged on the news by nearly 20% before markets opened Tuesday.
January 14, 2025
·
2 min read
·
Tristan Manalac
Duchenne muscular dystrophy
Regenxbio Gears Up to Challenge Sarepta in DMD as Gene Therapy Advances to Pivotal Studies
Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for 2026—potentially posing a threat to Sarepta’s Elevidys.
November 19, 2024
·
2 min read
·
Tristan Manalac
Business
REGENXBIO Announces Leadership Transition
REGENXBIO Inc. announced that Curran Simpson, Chief Operating Officer, has been appointed as President, Chief Executive Officer and a member of the Board of Directors, effective July 1, 2024.
June 12, 2024
·
8 min read
BioCapital
REGENXBIO to Participate in Upcoming May 2024 Investor Conferences
REGENXBIO Inc. announced it will participate in the following upcoming investor conferences.
May 10, 2024
·
1 min read
Drug Development
REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients
REGENXBIO Inc. (Nasdaq: RGNX) today announced it initiated enrollment in a new cohort of patients ages 1-3 in its Phase I/II AFFINITY DUCHENNE® trial to evaluate the safety and efficacy of RGX-202 in boys with Duchenne muscular dystrophy (Duchenne).
June 24, 2024
·
10 min read
BioCapital
REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024.
June 5, 2024
·
1 min read
Business
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
REGENXBIO Inc. announced financial results for the first quarter ending March 31, 2024.
May 8, 2024
·
13 min read
BioCapital
REGENXBIO to Participate in Upcoming March 2024 Investor Conferences
REGENXBIO Inc. announced it will participate the following upcoming investor conferences.
March 11, 2024
·
1 min read
BioCapital
REGENXBIO to Participate in Cantor Fitzgerald’s Virtual DMD and Other Dystrophy Days
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Cantor Fitzgerald’s Virtual DMD and Other Dystrophy Days on Wednesday, April 3, 2024.
March 27, 2024
·
1 min read
1 of 70,697
Next
